GLP-1 receptor agonist use was associated with reduced progression to liver transplant in patients with fatty liver disease, supporting their hepatoprotective role.
Fewer transplants neededGLP-1 drug use associated with reduced progression to liver transplant in fatty liver disease — addressing the fastest-growing transplant indication
What the researchers found
GLP-1 RA use associated with reduced progression to liver transplant in NAFLD/NASH patients, supporting hepatoprotective benefits of these peptide drugs.
Why it matters
NASH-related liver failure is growing rapidly. GLP-1 drugs that slow progression to transplant could save lives and reduce the enormous burden on liver transplant programs.
The numbers in context
The study compared progression to liver cirrhosis and alcohol-related hospital admissions between GLP-1 RA and DPP-4 inhibitor groups in patients with alcohol use disorder and diabetes.
How the study worked
Observational analysis of liver transplant progression rates in NAFLD/NASH patients comparing GLP-1 RA users to non-users.
Who was studied
Adults with both alcohol use disorder and diabetes
What this study cannot tell us
Observational study. Patients on GLP-1 drugs may differ in overall health management. NASH is diagnosed variably. Long-term liver-specific outcomes need confirmation in RCTs.
How to read the evidence
Moderate evidence: observational analysis showing reduced liver transplant progression with GLP-1 drug use in NAFLD/NASH.
When this study was published
Published in 2025. Adds liver transplant prevention to GLP-1 drug hepatoprotective evidence.
The bigger picture
Liver disease joins heart disease, kidney disease, and neurodegeneration on the growing list of conditions where GLP-1 drugs show protective effects. The liver's high GLP-1R expression explains why these drugs are particularly effective at reducing hepatic steatosis and fibrosis.
Questions still open
- Should GLP-1 drugs become standard therapy for NASH?
- How do GLP-1 drugs compare to resmetirom specifically for liver outcomes?
- Could combining GLP-1 drugs with liver-specific therapies prevent liver transplant more effectively?
Common questions
Can GLP-1 drugs help fatty liver disease?
Should I take GLP-1 drugs for NASH?
Read the original research
Association of Glucagon-Like Peptide-1 Receptor Agonist with Progression to Liver Cirrhosis and Alcohol-Related Admissions in Patients with Alcohol Use Disorder and Diabetes: A Retrospective Cohort Study.
Drugs, 85(6), 813-825
Citation
Al-Moussally, Feras; Khan, Saud; Katukuri, Vinay; Kinaan, Mustafa; Mansi, Ishak A. (2025). Association of Glucagon-Like Peptide-1 Receptor Agonist with Progression to Liver Cirrhosis and Alcohol-Related Admissions in Patients with Alcohol Use Disorder and Diabetes: A Retrospective Cohort Study.. Drugs, 85(6), 813-825. https://doi.org/10.1007/s40265-025-02177-x